Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (+)-pentazocine
2. D-pentazocine
3. Pentazocine, D-
4. Pentazocine, (+)-
5. 7361-76-4
6. Pentazocine 2s,6s,11s-form [mi]
7. A2g9vu2p2j
8. Chembl60542
9. (-)-pentazocine
10. 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-, (2s,6s,11s)-
11. (+)-[3h]-pentazocine
12. [3h]-(+)-pentazocine
13. Chembl2311194
14. (2s,6s,11s)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
15. (+)-alpha-pentazocine
16. Unii-a2g9vu2p2j
17. (+)-pen-tazocine
18. (+)-pentazocine, Solid
19. Schembl4461209
20. Dtxsid90870517
21. (+)-.alpha.-pentazocine
22. (2r,6r,11r)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
23. (6r,11s)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
24. 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
25. Zinc2015833
26. Bdbm50035131
27. Bdbm50423875
28. Pdsp2_001657
29. (-)-pentazocine, >=98% (hplc)
30. Q27273533
31. (+)-(6r,11s)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
32. (1s,9s,13s)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.0~2,7~]trideca-2,4,6-trien-4-ol
33. (2r,6r,11s)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
34. (2s,3r,6s,11s)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
35. (2s,6s,11s)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
36. 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-ethano-benzo[d]azocin-8-ol(+)-pentazocine
37. 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol ((+)-pentazocine)
38. 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol Anion
39. 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol((+)pentazocine)
| Molecular Weight | 285.4 g/mol |
|---|---|
| Molecular Formula | C19H27NO |
| XLogP3 | 3.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | 285.209264485 g/mol |
| Monoisotopic Mass | 285.209264485 g/mol |
| Topological Polar Surface Area | 23.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 414 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A D-Pentazocine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of D-Pentazocine, including repackagers and relabelers. The FDA regulates D-Pentazocine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. D-Pentazocine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A D-Pentazocine supplier is an individual or a company that provides D-Pentazocine active pharmaceutical ingredient (API) or D-Pentazocine finished formulations upon request. The D-Pentazocine suppliers may include D-Pentazocine API manufacturers, exporters, distributors and traders.
D-Pentazocine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of D-Pentazocine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right D-Pentazocine GMP manufacturer or D-Pentazocine GMP API supplier for your needs.
A D-Pentazocine CoA (Certificate of Analysis) is a formal document that attests to D-Pentazocine's compliance with D-Pentazocine specifications and serves as a tool for batch-level quality control.
D-Pentazocine CoA mostly includes findings from lab analyses of a specific batch. For each D-Pentazocine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
D-Pentazocine may be tested according to a variety of international standards, such as European Pharmacopoeia (D-Pentazocine EP), D-Pentazocine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (D-Pentazocine USP).
LOOKING FOR A SUPPLIER?
